Welcome to our dedicated page for Cineverse SEC filings (Ticker: CNVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cineverse Corp.’s streaming empire spans horror hits, anime cult classics, and FAST channels that beam Bob Ross to global TVs. That diversity makes its SEC paperwork dense with revenue mix tables, content-library amortisation schedules, and technology R&D footnotes. If you have ever searched "Cineverse SEC filings explained simply" you already know the challenge: hundreds of pages, dozens of exhibits, and fast-moving disclosure of new licensing deals.
Stock Titan solves that problem. Our AI reads every Cineverse annual report 10-K simplified, flags how SVOD vs AVOD sales shift, and summarises goodwill tests in plain English. The moment a Cineverse quarterly earnings report 10-Q filing or Cineverse 8-K material events explained hits EDGAR, you receive real-time access plus an AI-powered synopsis that highlights segment margins and subscriber growth. Need transaction details? The platform pulls Cineverse insider trading Form 4 transactions and pushes Cineverse Form 4 insider transactions real-time alerts so you can see when executives buy shares after a blockbuster premiere.
Investors, analysts, and content partners use these filings to:
- Track Matchpoint™ SaaS revenue acceleration inside the 10-K
- Compare cash burn to catalogue amortisation across quarters with one-click Cineverse earnings report filing analysis
- Review Cineverse proxy statement executive compensation to see bonuses tied to FAST channel viewership
- Monitor Cineverse executive stock transactions Form 4 alongside upcoming horror releases
Whether you’re understanding Cineverse SEC documents with AI for the first time or fine-tuning a valuation model, Stock Titan’s intelligent summaries, side-by-side comparisons, and historical archive put every disclosure in context—without wading through jargon.
Kineta, LLC (successor by merger to Kineta, Inc.) has filed nine Post-Effective Amendment No. 1s to previously effective Form S-8 registration statements to deregister all unsold shares that had been reserved for multiple legacy equity incentive and employee stock purchase plans. The administrative action follows the 30 June 2025 closing of the two-step merger in which Kineta became a wholly-owned subsidiary of TuHURA Biosciences, Inc. and was converted into Kineta, LLC. Because the stand-alone plans of Proteostasis Therapeutics, Yumanity Therapeutics and Kineta are now terminated, the related offerings are deemed concluded, triggering removal of the remaining registered securities. The amendments span Registration Statement Nos. 333-210521, 333-218544, 333-223664, 333-230155, 333-237181, 333-252691, 333-252692, 333-256853 and 333-268969, which collectively covered millions of potential shares across the 2008, 2016, 2018, 2020 and 2022 equity plans and various inducement grants. No new securities are being registered, no financial statements are provided, and the filing does not alter the merger consideration already distributed to former Kineta shareholders. The primary effect is the elimination of potential future dilution from the unissued shares and formal alignment of the capital structure with the post-merger entity.
Cineverse (NASDAQ:CNVS) filed a Form 8-K on June 27, 2025.
The sole disclosure (Item 2.02) states the company issued a press release announcing financial results for the three- and twelve-month periods ended March 31, 2025. The press release is furnished as Exhibit 99.1 and is deemed "furnished" rather than "filed," limiting Exchange Act liability and incorporation by reference.
No financial figures, guidance, or qualitative commentary are included in the body of the 8-K; therefore, investors must review Exhibit 99.1 for details.